| scholarly article | Q13442814 |
| P356 | DOI | 10.1200/JCO.2001.19.8.2282 |
| P8608 | Fatcat ID | release_xc7pmgyn3berfmkzwqgyfiax2y |
| P698 | PubMed publication ID | 11304782 |
| P2093 | author name string | R Wong | |
| J Maroun | |||
| G Batist | |||
| B Osterwalder | |||
| J Cox | |||
| P M Hoff | |||
| W Kocha | |||
| R Ansari | |||
| C Weaver | |||
| E Harrison | |||
| H U Burger | |||
| M Kuperminc | |||
| A O Wong | |||
| D Walde | |||
| P433 | issue | 8 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | colorectal cancer | Q188874 |
| colorectal carcinoma | Q25493920 | ||
| metastatic colon cancer | Q108566365 | ||
| capecitabine | Q420207 | ||
| fluorouracil | Q238512 | ||
| P304 | page(s) | 2282-2292 | |
| P577 | publication date | 2001-04-01 | |
| P1433 | published in | Journal of Clinical Oncology | Q400292 |
| P1476 | title | Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized phase III study | |
| P478 | volume | 19 |
| Q50710820 | 37th annual meeting of the American Society of Clinical Oncology. San Francisco, CA, May 12-15, 2001. |
| Q34180260 | 5-Fluorouracil or capecitabine in the treatment of advanced colorectal cancer: a pooled-analysis of randomized trials |
| Q28201937 | 5-Fluorouracil: mechanisms of action and clinical strategies |
| Q55515022 | 5-fluorouracil and cardiotoxicity: a review. |
| Q44255524 | A Phase I study of 9-nitrocamptothecin given concurrently with capecitabine in patients with refractory, metastatic solid tumors |
| Q33368148 | A Phase II study of capecitabine combined with gemcitabine in patients with advanced gallbladder carcinoma. |
| Q82758717 | A Phase II, open-label, randomised study to assess the efficacy and safety of the MEK1/2 inhibitor AZD6244 (ARRY-142886) versus capecitabine monotherapy in patients with colorectal cancer who have failed one or two prior chemotherapeutic regimens |
| Q42770955 | A Phase Ib pharmacokinetic study of the anti-angiogenic agent CKD-732 used in combination with capecitabine and oxaliplatin (XELOX) in metastatic colorectal cancer patients who progressed on irinotecan-based chemotherapy. |
| Q36070770 | A Phase Ib/II Study Evaluating the Combination of Weekly Docetaxel and Cisplatin Together with Capecitabine and Bevacizumab in Patients with Advanced Esophago-Gastric Cancer |
| Q55308824 | A Review of the Literature of Surgical and Nonsurgical Treatments of Invasive Squamous Cells Carcinoma. |
| Q46350339 | A case of cardiogenic shock caused by capecitabine treatment |
| Q34569995 | A case of long partial response to combination therapy of bevacizumab and capecitabine for liver metastases of rectal cancer |
| Q37131721 | A comparison between 5-fluorouracil/mitomycin and capecitabine/mitomycin in combination with radiation for anal cancer |
| Q44014861 | A dynamic model of hand-and-foot syndrome in patients receiving capecitabine |
| Q37225701 | A multicenter phase II study of the combination of oxaliplatin, irinotecan and capecitabine in the first-line treatment of metastatic colorectal cancer |
| Q43197898 | A new chemoimmunotherapy regimen (OXAFI) for advanced hepatocellular carcinoma |
| Q33358691 | A novel combination of cisplatin, irinotecan, and capecitabine in patients with advanced cancer |
| Q43962409 | A observational study of the efficacy and safety of capecitabine versus bolus infusional 5-fluorouracil in pre-operative chemoradiotherapy for locally advanced rectal cancer |
| Q36616386 | A phase I clinical and pharmacokinetic study of capecitabine (Xeloda) and irinotecan combination therapy (XELIRI) in patients with metastatic gastrointestinal tumours |
| Q33919101 | A phase I dose-escalation study of imatinib mesylate (Gleevec/STI571) plus capecitabine (Xeloda) in advanced solid tumors |
| Q34910416 | A phase I study of EKB-569 in combination with capecitabine in patients with advanced colorectal cancer |
| Q33973344 | A phase I study of an oral simulated FOLFOX with high dose capecitabine |
| Q33619858 | A phase I study of gefitinib, capecitabine, and celecoxib in patients with advanced solid tumors |
| Q46531270 | A phase I/II and pharmacokinetic study of irinotecan in combination with capecitabine as first-line therapy for advanced colorectal cancer |
| Q36858196 | A phase II study evaluating the use of concurrent mitomycin C and capecitabine in patients with advanced unresectable pseudomyxoma peritonei |
| Q36859180 | A phase II study of UFT with leucovorin administered as a twice daily schedule in the treatment of patients with metastatic colorectal cancer. |
| Q36694899 | A phase II study of capecitabine and docetaxel combination chemotherapy in patients with advanced gastric cancer |
| Q36097259 | A phase II study of capecitabine and lapatinib in advanced refractory colorectal adenocarcinoma: A Wisconsin Oncology Network study |
| Q44390789 | A phase II study of capecitabine in patients with recurrent and metastatic nasopharyngeal carcinoma pretreated with platinum-based chemotherapy |
| Q36614036 | A phase II study of capecitabine plus 3-weekly oxaliplatin as first-line therapy for patients with advanced gastric cancer |
| Q33399530 | A phase II study of capecitabine plus oxaliplatin as first-line chemotherapy in elderly patients with advanced gastric cancer |
| Q36105171 | A phase II study of capecitabine, oxaliplatin, and cetuximab with or without bevacizumab as frontline therapy for metastatic colorectal cancer. A Fox Chase extramural research study |
| Q36614004 | A phase II study of fixed-dose capecitabine and assessment of predictors of toxicity in patients with advanced/metastatic colorectal cancer |
| Q37234171 | A phase II study of leucovorin, 5-FU and docetaxel combination chemotherapy in patients with inoperable or postoperative relapsed gastric cancer |
| Q36671560 | A phase II trial of capecitabine (Xeloda®) in recurrent ovarian cancer |
| Q53280262 | A prospective study of XELIRI plus bevacizumab as a first-line therapy in Japanese patients with unresectable or recurrent colorectal cancer (KSCC1101). |
| Q36778075 | A prospective study of XELOX plus bevacizumab as first-line therapy in Japanese patients with metastatic colorectal cancer (KSCC 0902). |
| Q44433166 | A randomised study of protracted venous infusion of 5-fluorouracil (5-FU) with or without bolus mitomycin C (MMC) in patients with carcinoma of unknown primary |
| Q36131174 | A randomized phase II study of weekly nab-paclitaxel plus gemcitabine or simplified LV5FU2 as first-line therapy in patients with metastatic pancreatic cancer: the AFUGEM GERCOR trial |
| Q45236679 | A randomized phase II trial of capecitabine and two different schedules of irinotecan in first-line treatment of metastatic colorectal cancer: efficacy, quality-of-life and toxicity |
| Q35113026 | A retrospective study of first-line combination chemotherapy in advanced colorectal cancer: a Korean single-center experience |
| Q47291560 | A review of capecitabine-based adjuvant therapy for gastric cancer in the Chinese population |
| Q36661290 | A review of the role of capecitabine in the treatment of colorectal cancer. |
| Q33342817 | A single-institution experience with concurrent capecitabine and radiation therapy in gastrointestinal malignancies |
| Q90115442 | A study of capecitabine metronomic chemotherapy is non-inferior to conventional chemotherapy as maintenance strategy in responders after induction therapy in metastatic colorectal cancer |
| Q37149160 | Accomplishments in 2007 in the management of localized gastric cancer |
| Q45936600 | Acquired Fanconi syndrome after treatment with capecitabine, irinotecan, and bevacizumab. |
| Q35111174 | Adjuvant therapy for colon cancer in the new millenium. |
| Q37462241 | Adjuvant therapy for rectal cancer |
| Q34999400 | Adjuvant therapy in colon cancer: current status and future directions |
| Q36257130 | Adjuvant treatment strategies for early colon cancer |
| Q35376573 | Advanced molecular design of biopolymers for transmucosal and intracellular delivery of chemotherapeutic agents and biological therapeutics |
| Q38222249 | Advances in the management of colorectal cancer: from biology to treatment |
| Q84972669 | Advances in the treatment of metastatic colorectal cancer |
| Q41180643 | Alteration of Drug Sensitivity in Human Colon Cancer Cells after Exposure to Heat: Implications for Liver Metastasis Therapy using RFA and Chemotherapy. |
| Q36024905 | Altered deoxyuridine and thymidine in plasma following capecitabine treatment in colorectal cancer patients. |
| Q50041173 | An Update on Randomized Clinical Trials in Metastatic Colorectal Carcinoma |
| Q31106341 | An individual patient data meta-analysis of adjuvant therapy with uracil-tegafur (UFT) in patients with curatively resected rectal cancer. |
| Q88867253 | Association Between Serum Folate Level and Toxicity of Capecitabine During Treatment for Colorectal Cancer |
| Q34343967 | Bevacizumab in combination with biweekly capecitabine and irinotecan, as first-line treatment for patients with metastatic colorectal cancer |
| Q38672496 | Bevacizumab plus FOLFOX or FOLFIRI regimens on patients with unresectable liver-only metastases of metastatic colorectal cancer |
| Q36521850 | Biological agents versus chemotherapy in the treatment of colorectal cancer |
| Q37114675 | Biomarker in Colorectal Cancer. |
| Q37609130 | Biomarkers in precision therapy in colorectal cancer. |
| Q37598890 | Breast cancer: beyond the cutting edge |
| Q80510550 | Cancers of the large bowel and hepatobiliary tract |
| Q81086290 | Cancers of the large bowel and hepatobiliary tract |
| Q33847848 | Capecitabine and bevacizumab as first-line treatment in elderly patients with metastatic colorectal cancer |
| Q37122339 | Capecitabine and irinotecan with and without bevacizumab for advanced colorectal cancer patients |
| Q36615283 | Capecitabine and mitomycin C as third-line therapy for patients with metastatic colorectal cancer resistant to fluorouracil and irinotecan |
| Q37077342 | Capecitabine and timing of radiotherapy during preoperative chemoradiation for rectal cancer. |
| Q30673291 | Capecitabine as first-line treatment in colorectal cancer. Pooled data from two large, phase III trials |
| Q44228128 | Capecitabine combinations in the treatment of advanced colorectal cancer |
| Q37821286 | Capecitabine for locally advanced and metastatic colorectal cancer: A review |
| Q33426732 | Capecitabine in combination with either cisplatin or weekly paclitaxel as a first-line treatment for metastatic esophageal squamous cell carcinoma: a randomized phase II study |
| Q37400585 | Capecitabine in combination with irinotecan (XELIRI), administered as a 2-weekly schedule, as first-line chemotherapy for patients with metastatic colorectal cancer: a phase II study of the Spanish GOTI group |
| Q36694859 | Capecitabine in hormone-resistant metastatic prostatic carcinoma - a phase II trial |
| Q24633039 | Capecitabine in the management of colorectal cancer |
| Q35920292 | Capecitabine in the routine first-line treatment of elderly patients with advanced colorectal cancer--results from a non-interventional observation study. |
| Q36616002 | Capecitabine plus docetaxel every 3 weeks in first- and second-line metastatic oesophageal cancer: final results of a phase II trial |
| Q46965894 | Capecitabine plus oxaliplatin (xelox) in the treatment of chemotherapy-naive patients with metastatic colorectal cancer. |
| Q34639725 | Capecitabine plus oxaliplatin compared with 5-fluorouracil plus oxaliplatin in metastatic colorectal cancer: Meta-analysis of randomized controlled trials |
| Q46538590 | Capecitabine plus oxaliplatin for the first-line treatment of elderly patients with metastatic colorectal carcinoma: final results of the Southern Italy Cooperative Oncology Group Trial 0108. |
| Q37085987 | Capecitabine plus oxaliplatin for the treatment of colorectal cancer. |
| Q37154737 | Capecitabine, alone and in combination, in the management of patients with colorectal cancer: a review of the evidence |
| Q85177862 | Capecitabine-based chemotherapy for metastatic colorectal cancer |
| Q53249399 | Capecitabine-induced, nonneutropenic enterocolitis. |
| Q36342796 | Capecitabine/Oxaliplatin combinations in advanced colorectal cancer: summary of recent randomized studies. |
| Q34481305 | Capecitabine: a review of its use in the treatment of advanced or metastatic colorectal cancer |
| Q37303878 | Capecitabine: have we got the dose right? |
| Q88682206 | Cardiotoxicity of 5-fluorouracil and capecitabine in Chinese patients: a prospective study |
| Q37735615 | Cetuximab strongly enhances immune cell infiltration into liver metastatic sites in colorectal cancer |
| Q38002127 | Chemoprevention, chemotherapy, and chemoresistance in colorectal cancer. |
| Q36189950 | Chemoradiotherapy for colorectal cancer |
| Q30436646 | Chemoradiotherapy for gastrointestinal cancers |
| Q35572017 | Chemotherapeutic and biologic agents as radiosensitizers in rectal cancer |
| Q78478993 | Chemotherapy for colorectal cancer |
| Q53855896 | Chemotherapy of Metastatic Colorectal Cancer. |
| Q37602291 | Chemotherapy, which drugs and when |
| Q48268736 | Clinical Features of Metastatic Hepatic Malignancies. |
| Q49791896 | Clinical characteristics and treatment propensity in elderly patients aged over 80 years with colorectal cancer |
| Q91638619 | Clinical factors related to severe enterocolitis after adjuvant CAPOX for colorectal cancer: a retrospective analysis |
| Q64892570 | Clinical implementation of pre-treatment DPYD genotyping in capecitabine-treated metastatic breast cancer patients. |
| Q35188403 | Clinical pharmacokinetic/pharmacodynamic and physiologically based pharmacokinetic modeling in new drug development: the capecitabine experience |
| Q31027996 | Clinical relevance of DPYD variants c.1679T>G, c.1236G>A/HapB3, and c.1601G>A as predictors of severe fluoropyrimidine-associated toxicity: a systematic review and meta-analysis of individual patient data |
| Q37092129 | Colon cancer and the elderly: from screening to treatment in management of GI disease in the elderly. |
| Q35039124 | Colorectal cancer in the elderly: is palliative chemotherapy of value? |
| Q37044732 | Colorectal cancer with multiple metachronous metastasis achieving complete remission 14 years after surgical resection: report of a case |
| Q33735234 | Colorectal cancer: from prevention to personalized medicine. |
| Q36613503 | Combination chemotherapy with carboplatin, capecitabine and epirubicin (ECarboX) as second- or third-line treatment in patients with relapsed ovarian cancer: a phase I/II trial. |
| Q36084353 | Combination therapies with oxaliplatin and oral capecitabine or intravenous 5-FU show similar toxicity profiles in gastrointestinal carcinoma patients if hand-food syndrome prophylaxis is performed continuously |
| Q45090159 | Combination therapy with capecitabine and interferon alfa-2A in patients with advanced renal cell carcinoma: a phase II study |
| Q35875388 | Combined modality therapy for rectal cancer. |
| Q36598736 | Comparative effectiveness of chemotherapy in elderly patients with metastatic colorectal cancer |
| Q41231221 | Comparison between three oxaliplatin-based regimens with bevacizumab in patients with metastatic colorectal cancer |
| Q42794358 | Comparison of neoadjuvant oral chemotherapy with UFT plus Folinic acid or Capecitabine concomitant with radiotherapy on locally advanced rectal cancer |
| Q37323827 | Comparison of the efficacy of oral capecitabine versus bolus 5-FU in preoperative radiotherapy of locally advanced rectal cancer |
| Q46098962 | Complete Response of Para-Aortic and Lateral Pelvic Lymph Node Recurrence of Rectal Cancer Treated to S-1 Monotherapy |
| Q39063211 | Concurrent capecitabine and upper abdominal radiation therapy is well tolerated |
| Q64936195 | Construction of Marker-Free Genetically Modified Maize Using a Heat-Inducible Auto-Excision Vector. |
| Q46132535 | Costs associated with complications are lower with capecitabine than with 5-fluorouracil in patients with colorectal cancer |
| Q42775518 | Current and Novel Treatment Options for Metastatic Colorectal Cancer: Emphasis on Aflibercept |
| Q38628257 | Current and advancing treatments for metastatic colorectal cancer |
| Q36960766 | Current and emerging trends in the treatment of early-stage colorectal cancer: importance of a multidisciplinary approach |
| Q36626785 | Current directions in chemotherapy for colorectal cancer |
| Q57812660 | DPYD genotype-guided dose individualisation of fluoropyrimidine therapy in patients with cancer: a prospective safety analysis |
| Q47768032 | DPYD genotype-guided dose individualization to improve patient safety of fluoropyrimidine therapy: call for a drug label update |
| Q30244769 | Decision-making in geriatric oncology: systemic treatment considerations for older adults with colon cancer |
| Q38673003 | Decreased gastrointestinal toxicity associated with a novel capecitabine schedule (7 days on and 7 days off): a systematic review |
| Q37116834 | Definitive chemoradiotherapy with capecitabine and cisplatin in patients with esophageal cancer: a pilot study |
| Q38236614 | Delayed Presentation of DPD Deficiency in Colorectal Cancer. |
| Q39041183 | Design of novel chemotherapeutic delivery systems for colon cancer therapy based on oral polymeric nanoparticles |
| Q36936972 | Dihydro pyrimidine dehydrogenase deficiency in patients treated with capecitabine based regimens: a tertiary care centre experience |
| Q34427755 | Disease management considerations: disease management considerations |
| Q44002046 | Dose adaptation of capecitabine based on individual prediction of limiting toxicity grade: evaluation by clinical trial simulation |
| Q36306269 | Drug Insight: Metastatic colorectal cancer--oral fluoropyrimidines and new perspectives in the adjuvant setting |
| Q36646598 | EORTC Early Clinical Studies Group early phase II trial of S-1 in patients with advanced or metastatic colorectal cancer |
| Q37729193 | Economic evaluation of capecitabine as adjuvant or metastatic therapy in colorectal cancer |
| Q28066866 | Effect of Neoadjuvant Chemoradiotherapy with Capecitabine versus Fluorouracil for Locally Advanced Rectal Cancer: A Meta-Analysis |
| Q33831232 | Effect of a structured, active, home-based cancer-treatment program for the management of patients on oral chemotherapy |
| Q26865057 | Efficacy of S-1 vs capecitabine for the treatment of gastric cancer: a meta-analysis |
| Q37270388 | Efficacy of the oral fluorouracil pro-drug capecitabine in cancer treatment: a review |
| Q35125667 | Elective Bowel Resection for Incurable Stage IV Colorectal Cancer: Prognostic Variables for Asymptomatic Patients |
| Q35581170 | Emerging drugs in colorectal cancer |
| Q92185841 | Evaluating the recent developments in palliative chemotherapy for metastatic colorectal cancer |
| Q26752747 | Evidence-based medical oncology and interventional radiology paradigms for liver-dominant colorectal cancer metastases |
| Q37372475 | Evolution of nonsurgical therapy for colorectal cancer |
| Q43289305 | Feasibility and efficacy of capecitabine and FOLFIRI in patients aged 65 years and older with advanced colorectal cancer: a retrospective analysis |
| Q48177237 | First-line bolus 5-fluorouracil plus leucovorin for peritoneally disseminated gastric cancer with massive ascites or inadequate oral intake |
| Q38555200 | First-line chemotherapy for mCRC—a review and evidence-based algorithm. |
| Q36104929 | First-line therapy for advanced colorectal cancer |
| Q36760297 | First-line treatment strategies for elderly patients with metastatic colorectal cancer |
| Q35629061 | First-line treatment strategies to improve survival in patients with advanced colorectal cancer |
| Q36610452 | First-line treatment with oxaliplatin and capecitabine in patients with advanced or metastatic oesophageal cancer: a phase II study |
| Q38817372 | Fluoropyrimidine-Induced Cardiotoxicity: Manifestations, Mechanisms, and Management. |
| Q100426629 | From Tissue-Agnostic to N-of-One Therapies: (R)Evolution of the Precision Paradigm |
| Q40660694 | Future treatment options with capecitabine in solid tumours |
| Q55040134 | Geographical Variations in the Clinical Management of Colorectal Cancer in Australia: A Systematic Review. |
| Q55668963 | Germline pharmacogenomics of DPYD*9A (c.85T>C) variant in patients with gastrointestinal malignancies treated with fluoropyrimidines. |
| Q45040987 | Hand-foot syndrome in patients treated with capecitabine-containing combination chemotherapy |
| Q41844636 | Hand-foot syndrome with scleroderma-like change induced by the oral capecitabine: a case report |
| Q37214290 | Higher capecitabine AUC in elderly patients with advanced colorectal cancer (SWOGS0030). |
| Q50790500 | Highlights from: 42nd Annual Meeting of the American Society of Clinical Oncology. |
| Q80408154 | Highlights from: 5-Fluorouracil Drug Management Pharmacokinetics and Pharmacogenomics Workshop; Orlando, Florida; January 2007 |
| Q50577241 | Highlights from: XII European Cancer Conference, Copenhagen, Denmark, September 21-25, 2003. |
| Q35919188 | Hypokalemia secondary to capecitabine: a hidden toxicity? |
| Q36502358 | Identification of metastasis-associated genes in colorectal cancer using metaDE and survival analysis |
| Q90151718 | Identifying a Novel DPYD Polymorphism Associated with Severe Toxicity to 5-FU Chemotherapy in a Saudi Patient |
| Q40361727 | In vitro radiosensitization by oxaliplatin and 5-fluorouracil in a human colon cancer cell line |
| Q27028095 | Incidence and relative risk of grade 3 and 4 diarrhoea in patients treated with capecitabine or 5-fluorouracil: a meta-analysis of published trials |
| Q37355866 | Incidence and risk factors for capecitabine-induced symptomatic cardiotoxicity: a retrospective study of 452 consecutive patients with metastatic breast cancer. |
| Q33873230 | Increasing Access to Oral Anticancer Medicines in Middle-Income Countries: A Case Study of Private Health Insurance Coverage in Brazil. |
| Q100455599 | Individualized dosing of fluoropyrimidine-based chemotherapy to prevent severe fluoropyrimidine-related toxicity - What are the options? |
| Q44230410 | Inhibiting 5-fluorouracil breakdown: a broken down approach to 5-fluorouracil modulation |
| Q44217768 | Initial report of KSCC0803: feasibility study of capecitabine as adjuvant chemotherapy for stage III colon cancer in Japanese patients |
| Q34225660 | Integrating the oral fluoropyrimidines into the management of advanced colorectal cancer |
| Q92361660 | Integrative Gene Expression Profiling Analysis to Investigate Potential Prognostic Biomarkers for Colorectal Cancer |
| Q33344682 | Intermittent weekly high-dose capecitabine in combination with oxaliplatin: a phase I/II study in first-line treatment of patients with advanced colorectal cancer |
| Q73580657 | Intraoperative electron radiotherapy as a component of salvage therapy for patients with colorectal cancer and advanced nodal metastases |
| Q37394656 | Irinotecan as palliative chemotherapy for metastatic colorectal cancer: evolving tactics following initial treatment. |
| Q30470164 | Irinotecan-induced dysarthria. |
| Q48187299 | Is a nurse-led telephone intervention a viable alternative to nurse-led home care and standard care for patients receiving oral capecitabine? Results from a large prospective audit in patients with colorectal cancer |
| Q83305771 | Is oral tegafur with leucovorin equivalent to intravenous 5-fluorouracil and leucovorin in colorectal cancer? |
| Q36300533 | Japanese Society for Cancer of the Colon and Rectum (JSCCR) Guidelines 2014 for treatment of colorectal cancer |
| Q36324953 | Japanese Society for Cancer of the Colon and Rectum (JSCCR) guidelines 2016 for the treatment of colorectal cancer. |
| Q92776508 | Japanese Society for Cancer of the Colon and Rectum (JSCCR) guidelines 2019 for the treatment of colorectal cancer |
| Q37560984 | Laryngeal preservation in stage III/IV resectable laryngo-hypopharyngeal squamous cell carcinoma following concurrent chemoradiotherapy with capecitabine/cisplatin |
| Q44552839 | Lethal toxicity of capecitabine due to abusive folic acid prescription? |
| Q52765521 | Letter regarding Zhao et al. entitled " DPYD gene polymorphisms are associated with risk and chemotherapy prognosis in pediatric patients with acute lymphoblastic leukemia". |
| Q44228279 | Liquid chromatography-mass spectrometry method for the analysis of the anti-cancer agent capecitabine and its nucleoside metabolites in human plasma |
| Q37520492 | Long noncoding RNA GAPLINC promotes invasion in colorectal cancer by targeting SNAI2 through binding with PSF and NONO. |
| Q64257150 | Long-term survival of an elderly female with metastatic colon cancer after treated with capecitabine monotherapy |
| Q46765481 | Looking for the right drug for the right patient: a tale of old drugs and new pathways |
| Q35733020 | Low-dose capecitabine adjuvant chemotherapy in elderly stage II/III colorectal cancer patients (LC-ACEC): study protocol for a randomized controlled trial |
| Q33967458 | Maintenance therapy with capecitabine in patients with locally advanced unresectable pancreatic adenocarcinoma |
| Q34229432 | Maintenance therapy with capecitabine in patients with resected pancreatic adenocarcinoma after adjuvant therapy: a retrospective cohort study |
| Q38081864 | Management of advanced colorectal cancer, Part 1. |
| Q38057086 | Management of colon cancer: resource-stratified guidelines from the Asian Oncology Summit 2012. |
| Q35666090 | Management of colorectal cancer in elderly patients: focus on the cost of chemotherapy |
| Q34788235 | Management of colorectal cancer. |
| Q36615314 | Management of hand-foot syndrome induced by capecitabine |
| Q27026129 | Management of locally advanced and metastatic colon cancer in elderly patients |
| Q42661688 | Matuzumab plus epirubicin, cisplatin and capecitabine (ECX) compared with epirubicin, cisplatin and capecitabine alone as first-line treatment in patients with advanced oesophago-gastric cancer: a randomised, multicentre open-label phase II study. |
| Q42874419 | Medical oncology: A novel low-toxicity regimen for advanced colorectal cancer? |
| Q35076194 | Medical treatment of advanced colorectal cancer in 2009. |
| Q35532752 | Meta-analysis comparing the safety and efficacy of metastatic colorectal cancer treatment regimens, capecitabine plus irinotecan (CAPIRI) and 5-fluorouracil/leucovorin plus irinotecan (FOLFIRI). |
| Q34677913 | Metastatic colorectal cancer |
| Q35148795 | Metastatic colorectal cancer: systemic treatment in the new millennium |
| Q36607065 | Modern challenges in colorectal cancer. |
| Q83694425 | Modified FOLFOX6 with oxaliplatin stop-and-go strategy and oral S-1 maintenance therapy in advanced colorectal cancer: CCOG-0704 study |
| Q33440884 | Nab-paclitaxel plus either gemcitabine or simplified leucovorin and fluorouracil as first-line therapy for metastatic pancreatic adenocarcinoma (AFUGEM GERCOR): a non-comparative, multicentre, open-label, randomised phase 2 trial |
| Q36848090 | Neoadjuvant 5-FU or Capecitabine Plus Radiation With or Without Oxaliplatin in Rectal Cancer Patients: A Phase III Randomized Clinical Trial |
| Q88001745 | Neoadjuvant CapeOx therapy followed by sphincter-preserving surgery for lower rectal cancer |
| Q34006430 | Neoadjuvant capecitabine, radiotherapy, and bevacizumab (CRAB) in locally advanced rectal cancer: results of an open-label phase II study |
| Q35095353 | New developments in therapy for colorectal cancer |
| Q35875393 | New drugs for colorectal cancer. |
| Q35741932 | New systemic frontline treatment for metastatic colorectal carcinoma |
| Q48061495 | Novel Genetic Variants in Carboxylesterase 1 Predict Severe Early-Onset Capecitabine-Related Toxicity. |
| Q52599427 | Novel Therapeutic Targets in Cutaneous Squamous Cell Carcinoma. |
| Q35594038 | Novel chemotherapeutic and targeted agents in metastatic colorectal cancer: the time has arrived |
| Q35567292 | Nucleoside anticancer drugs: the role of nucleoside transporters in resistance to cancer chemotherapy |
| Q34530897 | Observations and hypothesis on an individual patient topically treated for capecitabine-induced Palmar-Plantar syndrome |
| Q37077204 | On the state of the art of adjuvant chemotherapy for colon cancer |
| Q37875058 | Optimal management of metastatic colorectal cancer: current status |
| Q37341676 | Optimal timing for the administration of capecitabine with preoperative chemoradiation for locally advanced rectal cancer |
| Q51046352 | Optimal use of adjuvant chemotherapy in stage II colorectal cancer. |
| Q44849722 | Oral 5-FU and digestive cancers |
| Q36822388 | Oral anticancer drugs in the elderly: an overview |
| Q30913489 | Oral capecitabine vs intravenous 5-fluorouracil and leucovorin: integrated efficacy data and novel analyses from two large, randomised, phase III trials |
| Q35055231 | Oral chemotherapy in colorectal cancer treatment: review of the literature. |
| Q30251387 | Oral drugs in the treatment of metastatic colorectal cancer |
| Q33442681 | Oral fluoropyrimidine versus intravenous 5-fluorouracil for the treatment of advanced gastric and colorectal cancer: meta-analysis |
| Q24239911 | Oral versus intravenous fluoropyrimidines for colorectal cancer |
| Q38650502 | Oral versus intravenous fluoropyrimidines for colorectal cancer. |
| Q35174812 | Oromandibular dystonia: a serious side effect of capecitabine. |
| Q39137546 | Overexpression of Lgr5 correlates with resistance to 5-FU-based chemotherapy in colorectal cancer |
| Q35201745 | Oxaliplatin and capecitabine chemotherapy for advanced colorectal cancer: a single institution's experience |
| Q33747440 | Oxaliplatin, irinotecan and capecitabine as first-line therapy in metastatic colorectal cancer (mCRC): a dose-finding study and pharmacogenomic analysis |
| Q35577933 | Oxaliplatin: A Novel Platinum Analog With Activity in Colorectal Cancer |
| Q34558173 | Palliative and adjuvant chemotherapy in colorectal cancer |
| Q34449797 | Panitumumab: the evidence of its therapeutic potential in metastatic colorectal cancer care. |
| Q38410725 | Paradoxical effect of capecitabine in 5-fluorouracil-induced cardiotoxicity: A case vignette and literature review. |
| Q42870250 | Patients With Locally Advanced and Metastatic Colorectal Cancer Treated With Capecitabine Versus 5-Fluorouracil as Monotherapy or Combination Therapy With Oxaliplatin: A Cost Comparison |
| Q39470148 | Patients homozygous for DPYD c.1129-5923C>G/haplotype B3 have partial DPD deficiency and require a dose reduction when treated with fluoropyrimidines |
| Q35444531 | Patients' self-reported adherence to capecitabine on XELOX treatment in metastatic colorectal cancer: findings from a retrospective cohort analysis |
| Q30227039 | Perceptions and Experiences of Patients Receiving Oral Chemotherapy |
| Q34731381 | Personalized colon cancer care in 2010. |
| Q38166233 | Personalizing colon cancer therapeutics: targeting old and new mechanisms of action. |
| Q79463052 | Pharmacokinetic and safety study of weekly irinotecan and oral capecitabine in patients with advanced solid cancers |
| Q26769850 | Pharmacologic resistance in colorectal cancer: a review |
| Q35182963 | Pharmacological factors influencing anticancer drug selection in the elderly |
| Q53641063 | Phase I clinical and pharmacokinetic study of S-1 plus oral leucovorin in patients with metastatic colorectal cancer. |
| Q36695872 | Phase I dose-escalation trial of irinotecan with continuous infusion 5-FU first line, in metastatic colorectal cancer |
| Q85026066 | Phase I dose-finding study of sorafenib in combination with capecitabine and cisplatin as a first-line treatment in patients with advanced gastric cancer |
| Q25256709 | Phase I study of intermittent and chronomodulated oral therapy with capecitabine in patients with advanced and/or metastatic cancer |
| Q34165276 | Phase I/II study of capecitabine plus oxaliplatin (XELOX) plus bevacizumab as first-line therapy in Japanese patients with metastatic colorectal cancer |
| Q46798803 | Phase I/II study of gefitinib and capecitabine in patients with colorectal cancer. |
| Q36201465 | Phase I/II trial of capecitabine, oxaliplatin, and irinotecan in combination with bevacizumab in first line treatment of metastatic colorectal cancer |
| Q41559464 | Phase I/II trial of dose-reduced capecitabine in elderly patients with advanced colorectal cancer. |
| Q36614888 | Phase II study of concurrent chemoradiotherapy with capecitabine and cisplatin in patients with locally advanced squamous cell carcinoma of the head and neck |
| Q44908377 | Phase II study of oral S-1 for treatment of metastatic colorectal carcinoma |
| Q46632523 | Phase II study of oral capecitabine in patients with hormone-refractory prostate cancer |
| Q34746009 | Phase II study of single agent capecitabine in the treatment of metastatic non-pancreatic neuroendocrine tumours |
| Q53476543 | Phase II trial of S-1 monotherapy in elderly or frail patients with metastatic colorectal cancer. |
| Q79508623 | Phase II trial of capecitabine and rHu-interferon-alpha-2a in patients with metastatic renal cell carcinoma, limited efficacy, and moderate toxicity |
| Q38775314 | Phase II trial of capecitabine plus erlotinib versus capecitabine alone in patients with advanced colorectal cancer |
| Q37386059 | Phase-II study of dose attenuated schedule of irinotecan, capecitabine, and celecoxib in advanced colorectal cancer |
| Q33370303 | Pilot study of postoperative adjuvant chemoradiation for advanced gastric cancer: adjuvant 5-FU/cisplatin and chemoradiation with capecitabine |
| Q52604710 | Plants and Surgery: The Protective Effects of Thymoquinone on Hepatic Injury-A Systematic Review of In Vivo Studies. |
| Q36671793 | Plasma concentrations of 5-fluorouracil and F-beta-alanine following oral administration of S-1, a dihydropyrimidine dehydrogenase inhibitory fluoropyrimidine, as compared with protracted venous infusion of 5-fluorouracil |
| Q35825206 | Population pharmacokinetics and concentration-effect relationships of capecitabine metabolites in colorectal cancer patients |
| Q35542484 | Postoperative Capecitabine with Concurrent Intensity-Modulated Radiotherapy or Three-Dimensional Conformal Radiotherapy for Patients with Stage II and III Rectal Cancer |
| Q36611129 | Postoperative chemoradiotherapy in gastric cancer -- a Phase I/II dose-finding study of radiotherapy with dose escalation of cisplatin and capecitabine chemotherapy |
| Q34569963 | Prediction of the response of colorectal cancer to systemic therapy |
| Q42722130 | Preferences of patients with advanced colorectal cancer for treatment with oral or intravenous chemotherapy |
| Q53662723 | Preliminary results of trial NPC-0501 evaluating the therapeutic gain by changing from concurrent-adjuvant to induction-concurrent chemoradiotherapy, changing from fluorouracil to capecitabine, and changing from conventional to accelerated radiother |
| Q37703496 | Preoperative chemoradiation in locally advanced rectal cancer: a comparison of bolus 5-fluorouracil/leucovorin and capecitabine |
| Q44146804 | Preoperative chemoradiation using oral capecitabine in locally advanced rectal cancer |
| Q37077330 | Preoperative chemoradiotherapy in the management of localized rectal cancer: the new standard. |
| Q33746816 | Prospective phase II study of preoperative chemoradiation with capecitabine in locally advanced rectal cancer |
| Q33620052 | Quality-of-life findings from a randomised phase-III study of XELOX vs FOLFOX-6 in metastatic colorectal cancer |
| Q35579304 | Radiotherapy and Oral Capecitabine in the Preoperative Treatment of Patients with Rectal Cancer: Rationale, Preliminary Results and Perspectives |
| Q44723860 | Randomized multicenter Phase II trial of two different schedules of irinotecan combined with capecitabine as first-line treatment in metastatic colorectal carcinoma |
| Q79846295 | Randomized trial of the efficacy of adjuvant chemotherapy for colon cancer with combination therapy incorporating the oral pyrimidine 1-hexylcarbamoyl-5-fluorouracil |
| Q42871713 | Randomized trial of two different doses of pyridoxine in the prevention of capecitabine‐associated palmar‐plantar erythrodysesthesia |
| Q34447526 | Recent advances in the management of colorectal cancer |
| Q36616519 | Recent advances in the systemic management of colorectal cancer |
| Q25257445 | Relationship between cyclooxygenase 8473T>C polymorphism and the risk of lung cancer: a case-control study |
| Q37573426 | Replacing 5-fluorouracil by capecitabine in localised squamous cell carcinoma of the anal canal: systematic review and meta-analysis |
| Q36615965 | Report of two protocol planned interim analyses in a randomised multicentre phase III study comparing capecitabine with fluorouracil and oxaliplatin with cisplatin in patients with advanced oesophagogastric cancer receiving ECF. |
| Q33455278 | Reporting of adverse events in randomized controlled trials of highly active antiretroviral therapy: systematic review |
| Q44700037 | Response of neoplastic meningitis from solid tumors to oral capecitabine |
| Q37009734 | Retrospective Analysis of Capecitabine and Radiation Therapy in the Treatment of Pancreatic Cancer |
| Q37560960 | Retrospective analysis of capecitabine and oxaliplatin (XELOX) plus bevacizumab as a first-line treatment for Japanese patients with metastatic colorectal cancer |
| Q97905332 | Retrospective study of preoperative chemoradiotherapy with capecitabine versus capecitabine plus oxaliplatin for locally advanced rectal cancer |
| Q27021105 | Review of systemic therapies for locally advanced and metastatic rectal cancer |
| Q64885950 | Revisiting the Clinical Importance of DPYD*9A (c.85T>C) Variant of Dihydropyrimidine Dehydrogenase (DPYD) Gene in Patients Treated with Fluoropyrimidine-Based Chemotherapy. |
| Q37692395 | Role of capecitabine in treating metastatic colorectal cancer in Chinese patients. |
| Q37113563 | Role of chemotherapy and novel biological agents in the treatment of elderly patients with colorectal cancer |
| Q37230238 | Role of oxaliplatin in the treatment of colorectal cancer |
| Q40068183 | Rs895819 in MIR27A improves the predictive value of DPYD variants to identify patients at risk of severe fluoropyrimidine-associated toxicity |
| Q33403790 | S-1 plus oxaliplatin versus capecitabine plus oxaliplatin for first-line treatment of patients with metastatic colorectal cancer: a randomised, non-inferiority phase 3 trial |
| Q89257709 | Second-Line Palliative Chemotherapy in Advanced Gall Bladder Cancer, CAP-IRI: Safe and Effective Option |
| Q45204578 | Second-line cetuximab/irinotecan versus oxaliplatin/fluoropyrimidines for metastatic colorectal cancer with wild-type KRAS. |
| Q37407092 | Second-look surgery following Hartmann's procedure for obstructive left-sided colorectal cancer |
| Q80871194 | Selective surgical treatment of patients with rectal carcinoma and unresectable synchronous metastases based on response to preoperative chemotherapy |
| Q24234461 | Sequential versus combination chemotherapy for advanced colorectal cancer |
| Q60629643 | Sequential versus combination chemotherapy for the treatment of advanced colorectal cancer (FFCD 2000–05): an open-label, randomised, phase 3 trial |
| Q34581085 | Sequential versus combination chemotherapy with capecitabine, irinotecan, and oxaliplatin in advanced colorectal cancer (CAIRO): a phase III randomised controlled trial |
| Q84453461 | Severe toxicity of capecitabine following uncomplicated treatment with 5-fluorouracil/leucovorin |
| Q38216008 | Should capecitabine replace 5-fluorouracil in the first-line treatment of metastatic colorectal cancer? |
| Q35584825 | Simplified prognostic model in patients with oxaliplatin-based or irinotecan-based first-line chemotherapy for metastatic colorectal cancer: a GERCOR study |
| Q53724796 | Simultaneous neoadjuvant radiochemotherapy with capecitabine and oxaliplatin for locally advanced rectal cancer. Treatment outcome outside clinical trials. |
| Q50872828 | Single-agent capecitabine as maintenance therapy after induction of XELOX (or FOLFOX) in first-line treatment of metastatic colorectal cancer: randomized clinical trial of efficacy and safety. |
| Q35103614 | Stage III colon cancer at Baylor University Medical Center at Dallas and the Baylor Sammons Cancer Center: experience from 2000 to 2004 |
| Q57471266 | Survival outcome and prognostic model of patients with colorectal cancer on phase 1 trials |
| Q58614342 | Systemic Therapy for Patients with Colorectal Cancer: State of the Art |
| Q95806910 | Systemic chemotherapy with doxorubicin, cisplatin and capecitabine for metastatic hepatocellular carcinoma |
| Q46500265 | Systemic therapy for colorectal cancer |
| Q35572015 | Systemic therapy for colorectal cancer: focus on newer chemotherapy and novel agents |
| Q37109507 | Systemic therapy for metastatic colorectal cancer: current questions |
| Q81253030 | Systemic treatment of colorectal cancer |
| Q36217126 | Targeted drugs in metastatic colorectal cancer with special emphasis on guidelines for the use of bevacizumab and cetuximab: an Acta Oncologica expert report |
| Q37158228 | Targeted therapeutic agents for colorectal cancer |
| Q39233316 | The Role of Fluoropirimidines in Gastrointestinal Tumours: from the Bench to the Bed. |
| Q37328589 | The Value of Restaging With Chest and Abdominal CT/MRI Scan After Neoadjuvant Chemoradiotherapy for Locally Advanced Rectal Cancer. |
| Q24652904 | The clinical and economic benefits of capecitabine and tegafur with uracil in metastatic colorectal cancer |
| Q34980526 | The dual role of thymidine phosphorylase in cancer development and chemotherapy |
| Q39102953 | The effects of silencing of PI3K p85α on 5-FU-induced colorectal cancer cells apoptosis |
| Q41231669 | The efficacy and safety of capecitabine plus bevacizumab combination as first-line treatment in elderly metastatic colorectal cancer patients |
| Q34773758 | The efficacy of additional bevacizumab to cytotoxic chemotherapy regimens for the treatment of colorectal cancer: an updated meta-analysis for randomized trials |
| Q41083423 | The rapidly escalating cost of treating colorectal cancer in Australia. |
| Q36101808 | The role of chemotherapy in colon cancer. |
| Q33183187 | The use of oral cytotoxic and cytostatic drugs in cancer treatment |
| Q38842633 | Therapeutic drug monitoring of 5-fluorouracil. |
| Q26777679 | Therapeutic potential of TAS-102 in the treatment of gastrointestinal malignancies |
| Q80510490 | Thymidylate synthase inhibitors |
| Q37653406 | Tolerability of Capecitabine Monotherapy in Metastatic Colorectal Cancer: A Real-World Study |
| Q53622588 | Treatment of High-Grade Metastatic Pancreatic Neuroendocrine Carcinoma with FOLFIRINOX. |
| Q44457418 | Treatment of advanced colorectal carcinoma with oxaliplatin and capecitabine: a phase II trial |
| Q36276360 | Treatment of elderly cancer patients with chemotherapy |
| Q57071081 | Treatment of patients with metastatic colorectal cancer and poor performance status: current evidence and challenges |
| Q37649832 | Trends in treatment and survival in older patients presenting with stage IV colorectal cancer |
| Q37340518 | Twelve weeks of protracted venous infusion of fluorouracil (5-FU) is as effective as 6 months of bolus 5-FU and folinic acid as adjuvant treatment in colorectal cancer |
| Q40127619 | Uncommon dihydropyrimidine dehydrogenase mutations and toxicity by fluoropyrimidines: a lethal case with a new variant. |
| Q28085651 | Unresolved issues and controversies surrounding the management of colorectal cancer liver metastasis |
| Q93635367 | Upcoming articles |
| Q37815612 | Update on capecitabine alone and in combination regimens in colorectal cancer patients |
| Q34711507 | Which endpoints should we use in evaluating the use of novel fluoropyrimidine regimens in colorectal cancer? |
| Q33370632 | XELOX (capecitabine plus oxaliplatin) as first-line treatment for elderly patients over 70 years of age with advanced colorectal cancer |
| Q34630237 | XELOX vs FOLFOX-4 as first-line therapy for metastatic colorectal cancer: NO16966 updated results. |
| Q79769145 | [A review of chemotherapy for metastatic colon cancer] |
| Q45990468 | [Therapeutic use and profile of toxicity of the FOLFOX4 regimen]. |
Search more.